Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Fund Letter | C.T. FitzpatrickVulcan Value Partners - Large Cap | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace Holdings Inc.) Medpace is a global clinical contract research organization featuring a robust balance sheet and strong cash generation. While near-term growth... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | John Brown, Drew JustmanMadison Dividend Income Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace) Our investments in drug development companies like Charles River Labs (CRL) and Medpace Holdings (MEDP) pulled back, driven by AI disruption fears. | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Spyglass Capital | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace Holdings, Inc.) Medpace posted strong Q2 results that beat expectations on both top and bottom lines, leading to a full-year guidance upgrade. Furthermore, massive share... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Vulcan Value Partners LLCVulcan Value Partners Focus Plus | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace Holdings, Inc.) Medpace continues to outperform expectations by winning business awards and expanding free cash flow despite biotech funding noise. A debt-free balance... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Jordan McNameeOptimist Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace Holdings, Inc.) Position initiated in April. Reported one of... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | C.T. FitzpatrickVulcan Value Partners - Small Cap | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace Holdings, Inc.) Medpace delivers superior financial performance by managing outsourced clinical trials for biotech clients. Despite broad sector... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | LVS Advisory LLCLVS Advisory - Growth | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace) LVS Advisory favors Medpace's focus on serving small biotech companies with full-service CRO work over Icon's large pharma roll-up strategy. The manager doubled... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | C.T. FitzpatrickVulcan Value Partners - All Cap | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace Holdings, Inc.) Medpace outperformed expectations across net new business awards, revenue, and cash conversion despite broader biotech funding headwinds. Initial 2024 financial... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Vulcan Value Partners LLCVulcan Value Partners Focus Plus | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace Holdings Inc.) Medpace operates an attractive outsourced drug development model serving small and midsized biotech firms. Despite expecting flat... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | LVS Advisory LLCLVS Advisory - Event Driven | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace) LVS is highly optimistic about Medpace because its focused business model of serving small biotech companies with full-service CRO work is structurally superior to serving large pharma. LVS reinforced its... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Vulcan Value Partners, LLCVulcan Value Partners - Focus | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace Holdings, Inc.) Medpace outperformed expectations with robust new contract wins and strong cash generation despite biotech funding headwinds. The company issued... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | C.T. FitzpatrickVulcan Value Partners - Small Cap | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long MEDP (Medpace Holdings Inc.) The manager highlights Medpace's full-service model which serves price-insensitive small to mid-sized biotech companies lacking internal clinical trial infrastructure. The company features... | BULL | View Pitch → | |
| Jan 20, 2026 | Fund Letter | Kris Webster, Michael Poulsen, and Jack McManusCanopy Investors | Life Sciences Tools & ServicesLife Sciences Tools & Services | Canopy Investors 2025 Q4 (MEDP) Medpace was the Fund's largest contributor in H1 FY26, having been among its largest detractors over the prior 12 months. Medpace is a... | BULL | View Pitch → | |
| Dec 3, 2025 | Fund Letter | Kris Webster, Michael Poulsen, and Jack McManusCanopy Investors | Life Sciences Tools & ServicesLife Sciences Tools & Services | Canopy Investors 2025 Q3 (MEDP) Medpace increased by 8%. Medpace is a... | BULL | View Pitch → | |
| Nov 28, 2025 | Fund Letter | Haruki Toyama, Andy Romanowich, Rich EisingerMadison Mid Cap Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Madison Mid Cap Fund 2025 Q3 (MEDP) Medpace posted accelerating revenue and bookings growth in 2Q 2025, defying industry expectations of a slowdown in contract research activity. Management expressed confidence... | BULL | View Pitch → | |
| Nov 28, 2025 | Fund Letter | Jordan McNameeOptimist Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Optimist Fund 2025 Q3 (MEDP) Medpace is one of the leading contract research organizations (CROs) focused on small and mid-sized biotech companies. Founded in the... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.